Mary Madison, RN, RAC-CT, CDP
Clinical Consultant – Briggs Healthcare
On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm™) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer’s disease. From the onset, CMS ran a transparent, evidence-based process that incorporated more than 10,000 stakeholder comments and more than 250 peer-reviewed documents into the determination.
As a part of CMS’ continued commitment to engage stakeholders on an ongoing basis, CMS will hold a national stakeholder call on May 11, 2022 to review the recent finalized coverage decision on monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s Disease. CMS will review the overall coverage process, the finalized decision, and address questions as time allows.
When: Wednesday, May 11, 2022, 11:00 AM ET
Who should attend: This stakeholder call is intended for anyone in the healthcare industry, but specifically for healthcare issuers, providers of healthcare, and healthcare advocates.
After registering, you will receive a confirmation email containing information about joining the webinar.
This meeting is closed to press.
- For the complete press release visit: https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment
- For a fact sheet on Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease, visit: https://www.cms.gov/newsroom/fact-sheets/medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment-alzheimers-disease.
To read the final NCD CED decision memorandum, visit: https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305.